Sana Biotechnology (SANA) Free Cash Flow (2020 - 2026)

Sana Biotechnology (SANA) has 7 years of Free Cash Flow data on file, last reported at -$37.7 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 22.8% year-over-year to -$37.7 million; the trailing twelve-month figure through Mar 2026 stood at -$133.6 million (up 32.48% YoY), and the FY2025 full-year result was -$144.8 million, up 35.13% from the prior year.
• Free Cash Flow retreated to -$37.7 million in Q1 2026, from -$33.5 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$29.5 million in Q3 2025 to a low of -$81.4 million in Q1 2023.
• A 5-year average of -$56.5 million and a median of -$55.3 million in 2022 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow tumbled 95.96% in 2022 and surged 39.44% in 2025, its largest moves.
• Tracing SANA's Free Cash Flow over 5 years: stood at -$74.9 million in 2022, then advanced by 25.97% to -$55.4 million in 2023, then climbed by 15.4% to -$46.9 million in 2024, then gained by 28.55% to -$33.5 million in 2025, then retreated by 12.39% to -$37.7 million in 2026.
• Business Quant data shows SANA's Free Cash Flow at -$37.7 million in Q1 2026, -$33.5 million in Q4 2025, and -$29.5 million in Q3 2025.